º£½ÇÊÓÆµ

Oops.

Our website is temporarily unavailable in your location.

We are working hard to get it back online.

PRIVACY
Enterprise

North East deals of the week: key contracts, investments and acquisitions

This week's round-up includes Notify Technology, Lant Medical, Fenwick and Colmans, Fairgrieve Compression Moulding and Steel River Consultants

Notify Technology: left to right, Natalia Blagburn, Andy Dumbell, Duncan Davies and Ian Wilson(Image: Notify Technology)

A Tyneside safety tech business is set to tap into new AI features on the back of a £1.5m investment boost.

Notify Technology was launched in in 2017 by Duncan Davies and Andy Dumbell to help businesses to digitally record information through a platform designed to improve health and safety at work. Its platform allows clients to document everything from accidents and near misses to complete audits, inspections and risk assessments, and to manage safety documents and analyse safety data from one central location.

Now the firm, whose clients include McDonalds, Siemens and the NHS, has raised a further £1.5m from Calculus Capital, the North East Venture Fund supported by the European Regional Development Fund and managed by Mercia Ventures, and private investors.

Notify Technology will use the funding to boost its platform with the addition of new AI-powered features and to accelerate its sales and marketing operations.

Duncan Davies, co-founder and CEO, said: “Notify has become the challenger brand in Safety Tech through our approach to service and innovation, delivered by a fantastic team. I’m delighted we’ve been able to raise additional capital from long term investors to support our latest innovations and to continue our growth trajectory. Thousands of organisations are recognising the value of looking after the health, safety and wellbeing of their workforce, and Notify is now perfectly placed to deliver software that drives employee engagement and productivity.”

Joanne Lant, founder of Lant Medical(Image: Lant Medical)


A Northumberland life sciences firm has sealed a £500,000 investment to ramp up work on a new cancer-prevention treatment. Lant Medical has secured £500,000 investment from Innovate º£½ÇÊÓÆµ, the º£½ÇÊÓÆµ’s innovation agency, and two angel investors from the Northern Investor Hub, to design a clinical trial for a promising new non-antibiotic treatment which is designed to eradicate cancer-causing bacteria.

The Alnwick based business, founded by CEO Joanne Lant, will use the funding to design a clinical trial for the treatment, which targets H. Pylori, the most common pathogenic bacteria in the world. Around half the world’s population is infected with the bacteria but current treatment options remain limited and problematic.

H. pylori infections are treated with two or three antibiotics simultaneously, which Ms Lant says often leads to incomplete eradication and it is a worldwide concern that antibiotics are gaining resistance. The firm's first product - HELIX - aims treats the root cause and all the symptoms of H. pylori, and it aims to be an over-the-counter therapy.